A Study to Evaluate Cardiotoxicity in Total Hip and Knee Arthroplasty

Overview

About this study

The purposes of this study are to determine: the risk of cardiomyopathy and heart failure, and cardiac structure and function in patients with THA and TKA. This study will also determine the association between serum and/or synovial fluid metal ion levels with cardiac structure and function in 100 prospectively-recruited THA and TJA patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) patients who had surgery at least 10 years ago.
THA and TKA patients presenting with high metal levels or adverse local tissue reactions (high priority group for recruitment).
Patients scheduled for revision for osteolysis, loosening, wear, pain.

Exclusion Criteria:

Revision THA or TKA for infection, dislocation, periprosthetic fracture.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Hilal Maradit Kremers, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Hilal Maradit Kremers, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials